Literature DB >> 19409930

Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes.

Chunxia Zhao1, Charles Jefferson Crews, Cynthia A Derdeyn, Jerry L Blackwell.   

Abstract

Adenovirus (Ad) vectors have been developed as human immunodeficiency-1 (HIV-1) vaccine vectors because they consistently induce immune responses in preclinical animal models and human trials. Strong promoters and codon-optimization are often used to enhance vaccine-induced HIV-1 gene expression and immunogenicity. However, if the transgene is inherently cytotoxic in the cell line used to produce the vector, and is expressed at high levels, it is difficult to rescue a stable Ad HIV-1 vaccine vector. Therefore we hypothesized that generation of Ad vaccine vectors expressing cytotoxic genes, such as HIV-1 env, would be more efficient if expression of the transgene was down-regulated during Ad rescue. To test this hypothesis, a Lac repressor-operator system was applied to regulate expression of reporter luciferase and HIV-1 env transgenes during Ad rescue. The results demonstrate that during Ad rescue, constitutive expression of the Lac repressor in 293 cells reduced transgene expression levels to approximately 5% of that observed in the absence of regulation. Furthermore, Lac-regulation translated into more efficient Ad rescue compared to traditional 293 cells. Importantly, Ad vectors rescued with this system showed high levels of transgene expression when transduced into cells that lack the Lac repressor protein. The Lac-regulated system also facilitated the rescue of modified Ad vectors that have non-native receptor tropism. These tropism-modified Ad vectors infect a broader range of cell types than the unmodified Ad, which could increase their effectiveness as a vaccine vector. Overall, the Lac-regulated system described here (i) is backwards compatible with Ad vector methods that employ bacterial-mediated homologous recombination, (ii) is adaptable for the engineering of tropism-modified Ad vectors, and (iii) does not require co-expression of regulatory genes from the vector or the addition of exogenous chemicals to induce or repress transgene expression. This system therefore could facilitate the development of Ad-based vaccine candidates that otherwise would not be feasible to generate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409930      PMCID: PMC2704014          DOI: 10.1016/j.jviromet.2009.04.028

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  78 in total

1.  Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule.

Authors:  Alexander V Pereboev; Jill M Nagle; Mikhail A Shakhmatov; Pierre L Triozzi; Qiana L Matthews; Yosuke Kawakami; David T Curiel; Jerry L Blackwell
Journal:  Mol Ther       Date:  2004-05       Impact factor: 11.454

2.  A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1.

Authors:  George T Mercier; Jacquelyn A Campbell; James D Chappell; Thilo Stehle; Terence S Dermody; Michael A Barry
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

3.  The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3.

Authors:  Dominique Sirena; Benjamin Lilienfeld; Markus Eisenhut; Stefan Kälin; Karin Boucke; Roger R Beerli; Lorenz Vogt; Christiane Ruedl; Martin F Bachmann; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.

Authors:  J Sodroski; W C Goh; C Rosen; K Campbell; W A Haseltine
Journal:  Nature       Date:  1986 Jul 31-Aug 6       Impact factor: 49.962

5.  The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion.

Authors:  J V Maizel; D O White; M D Scharff
Journal:  Virology       Date:  1968-09       Impact factor: 3.616

6.  Contagious apoptosis facilitated by the HIV-1 envelope: fusion-induced cell-to-cell transmission of a lethal signal.

Authors:  Karine Andreau; Jean-Luc Perfettini; Maria Castedo; Didier Métivier; Véronique Scott; Gérard Pierron; Guido Kroemer
Journal:  J Cell Sci       Date:  2004-10-19       Impact factor: 5.285

7.  Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter.

Authors:  S K Mittal; M R McDermott; D C Johnson; L Prevec; F L Graham
Journal:  Virus Res       Date:  1993-04       Impact factor: 3.303

8.  Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors:  Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

9.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Authors:  P L Earl; C C Broder; D Long; S A Lee; J Peterson; S Chakrabarti; R W Doms; B Moss
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  2 in total

1.  Differential binding of the HIV-1 envelope to phosphatidylserine receptors.

Authors:  Linlin Gu; Brian Sims; Alexandre Krendelchtchikov; Edlue Tabengwa; Qiana L Matthews
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-06-13       Impact factor: 3.747

2.  HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach.

Authors:  Qiana L Matthews; Aiman Fatima; Yizhe Tang; Brian A Perry; Yuko Tsuruta; Svetlana Komarova; Laura Timares; Chunxia Zhao; Natalia Makarova; Anton V Borovjagin; Phoebe L Stewart; Hongju Wu; Jerry L Blackwell; David T Curiel
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.